108 related articles for article (PubMed ID: 32837100)
21. Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India.
Solo P; Doss MA
Curr Res Pharmacol Drug Discov; 2021; 2():100065. PubMed ID: 34870160
[TBL] [Abstract][Full Text] [Related]
22. Molecular docking studies of phytochemicals from
Sarkar A; Agarwal R; Bandyopadhyay B
J Ayurveda Integr Med; 2022; 13(2):100557. PubMed ID: 35185301
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
24. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
25. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
Kiran G; Karthik L; Shree Devi MS; Sathiyarajeswaran P; Kanakavalli K; Kumar KM; Ramesh Kumar D
J Ayurveda Integr Med; 2022; 13(1):100324. PubMed ID: 32527713
[TBL] [Abstract][Full Text] [Related]
26. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
27. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.
Enmozhi SK; Raja K; Sebastine I; Joseph J
J Biomol Struct Dyn; 2021 Jun; 39(9):3092-3098. PubMed ID: 32329419
[TBL] [Abstract][Full Text] [Related]
28. Potential role of nicotinamide analogues against SARS-COV-2 target proteins.
Arora MK; Grover P; Asdaq SMB; Mehta L; Tomar R; Imran M; Pathak A; Jangra A; Sahoo J; Alamri AS; Alsanie WF; Alhomrani M
Saudi J Biol Sci; 2021 Dec; 28(12):7567-7574. PubMed ID: 34608370
[TBL] [Abstract][Full Text] [Related]
29. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Singh SK; Upadhyay AK; Reddy MS
3 Biotech; 2021 Feb; 11(2):93. PubMed ID: 33520579
[TBL] [Abstract][Full Text] [Related]
30. Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.
Batool A; Bibi N; Amin F; Kamal MA
Eur J Pharmacol; 2021 Feb; 892():173779. PubMed ID: 33275961
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
32. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
33. Computer Aided Drug Design Approach to Screen Phytoconstituents of
Siva Kumar B; Anuragh S; Kammala AK; Ilango K
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207602
[TBL] [Abstract][Full Text] [Related]
34. Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation.
Natesh J; Mondal P; Penta D; Abdul Salam AA; Meeran SM
Comput Biol Med; 2021 Jan; 128():104102. PubMed ID: 33190011
[TBL] [Abstract][Full Text] [Related]
35. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.
Shawan MMAK; Halder SK; Hasan MA
Bull Natl Res Cent; 2021; 45(1):27. PubMed ID: 33495684
[TBL] [Abstract][Full Text] [Related]
36. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
37. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
[TBL] [Abstract][Full Text] [Related]
38. Ayurvedic treatment of COVID-19: A case report.
Girija PLT; Sivan N
J Ayurveda Integr Med; 2022; 13(1):100329. PubMed ID: 32680602
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling study of tectoquinone and acteoside from
Kallingal A; Thachan Kundil V; Ayyolath A; Karlapudi AP; Muringayil Joseph T; E JV
J Biomol Struct Dyn; 2022 Mar; 40(4):1764-1775. PubMed ID: 33036548
[TBL] [Abstract][Full Text] [Related]
40. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
